Exploring the Relationship Between Comorbidities and Alzheimer's Disease Progression Assessed Using the Clinical Dementia Rating Scale: A Systematic Literature Review

Author(s)

Cummings J1, Hahn-Pedersen JH2, Eichinger C3, Freeman C3, Clark A2, Lanctôt K4
1Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, USA, 2Novo Nordisk A/S, Søborg, Denmark, 3Oxford PharmaGenesis, Oxford, UK, 4Hurvitz Brain Sciences Program Sunnybrook Research Institute, Toronto, ON, Canada

OBJECTIVES: Many patients with Alzheimer’s disease (AD) have comorbidities such as cardiovascular disease (CVD). AD symptoms such as neuropsychiatric symptoms (NPS) and urinary incontinence (UI) may also be considered as comorbidities. However, data synthesis is required on the progression of comorbidities with increasing AD severity, and the role of comorbidities in AD progression. We designed a systematic literature review to identify studies that assessed associations between comorbidities in AD and Clinical Dementia Rating (CDR) scale Global or Sum of Boxes (CDR-SB) scores, two widely used AD staging measures.

METHODS: Embase, MEDLINE and the Cochrane Library were searched on 26 November 2021 using terms for AD, CDR/CDR-SB, and comorbidities, without date restriction. All AD stages (mild cognitive impairment and mild, moderate and severe dementia) and study designs were considered relevant.

RESULTS: Overall, 30 studies met the inclusion criteria, of which 14 were full publications that reported detailed data on the association between CDR/CDR-SB scores and comorbidities. Together, these included nearly 7000 patients. Six studies reported data on NPS, most of which indicated that NPS become more frequent with increasing AD severity (higher CDR/CDR-SB scores). In one study, the presence of NPS at baseline predicted AD progression, and AD severity at baseline was linked to subsequent NPS progression. Another study found that increasing CDR scores over time are linked to the progression of depressive symptoms. Five studies reported data on CVD or cardiovascular risk factors; however, no clear association between CVD and AD severity or progression was identified. Two studies found that urge UI is associated with AD severity.

CONCLUSIONS: The link between comorbidities and AD severity measured using the CDR or CDR-SB has not been extensively studied. Although a link between NPS and AD is well established, the interrelationship between AD progression and other conditions remains unknown and requires further investigation.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

SA75

Topic

Study Approaches

Topic Subcategory

Literature Review & Synthesis

Disease

SDC: Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×